CME

Jointly provided by the Postgraduate Institute for Medicine and DKBmed, LLC.

Learning Objectives

After completing this activity, the participant should be better able to:

  1. Explain the risk factors for diabetic retinopathy (DR) and the importance of early screening.
  2. Describe the American Diabetes Association and American Association of Ophthalmology recommendations for retinal screening of all patients with diabetes.
  3. Describe the benefits of current treatment options for DR, including VEGF inhibitors.

Target Audience

This activity is intended for primary care clinicians and allied health providers who treat patients with type 2 diabetes.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Acknowledgement

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty / Presenter Reported Financial Relationship

Scott Musick, DO

  • Speakers Bureau/Honoraria for Non-CME: Amgen, AstraZeneca, Bayer, Abbvie
  • Consultant/Advisory Board: CIN Medical Board

Planners and Managers

The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Launch: October 17, 2022
Expiration: October 16, 2023

Contact Information

If you have questions regarding the certification of this activity, please contact PIM via email at [email protected]. For technical issues, please. contact [email protected]